VICTORIA, BC, Nov. 3, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE: TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced a research partnership
with Mila, a world-renowned research institute dedicated to
artificial intelligence (AI) development and focused on deep
learning optimization for AI and machine language learning.
ImmunoPrecise and Mila will collaborate on research and talent
development initiatives as the Company continues to advance next
generation innovation in therapeutics. The collaboration will
leverage data and artificial intelligence to transform how novel
therapeutics are discovered and developed. Founded by
Professor Yoshua Bengio,
co-recipient of the 2018 Turing Prize, the Mila Institute is
recognized worldwide for its significant contributions in the field
of deep learning and has established itself in the fields of
language modeling, machine translation, object recognition, and
generative design.
"This partnership opens up an exciting opportunity for AI to tap
into unexplored datasets generated by ImmunoPrecise's effective and
high-throughput therapeutic antibody discovery platforms, to
contribute to the design of new therapeutics against
life-threatening diseases that challenge humanity," stated Mila
Founder, Yoshua Bengio.
"This partnership reflects IPA's deep-seeded commitment to
innovation," said Dr. Jennifer Bath,
CEO of ImmunoPrecise. "Combining our efforts with the
world-renowned talent at Mila catalyzes our advancements beyond the
traditional life science model, as we continue to embrace the
future of therapeutic discovery to accelerate the commercialization
of life saving therapeutics."
This partnership comes on the heels of ImmunoPrecise engaging
LaPorte Expert Conseil Inc., with whom the Company has recently
completed a feasibility study for the design of a Good
Manufacturing Practices (GMP) facility. ImmunoPrecise's
partnerships with Mila and LaPorte were facilitated by Montréal
International, an economic promotion agency focused on the growth
of Greater Montréal, as a part of Montréal International's ongoing
efforts to support ImmunoPrecise in leveraging unique life science
and technology partnerships.
About Mila
Founded in 1993 by Professor Yoshua Bengio of the Université de Montréal,
Mila is a research institute in artificial intelligence which
rallies 500 researchers specializing in the field of deep learning.
Based in Montréal, Mila's mission is to be a global pole for
scientific advances that inspires innovation and the development of
AI for the benefit of all.
Since 2017, Mila is the result of a partnership between the
Université de Montréal and McGill
University, closely linked with Polytechnique Montréal and
HEC Montréal, and gathers in its offices a community of professors,
students, industrial partners and startups working in AI, making
the institute the world's largest academic research center in deep
learning.
Mila, a non-profit organization, is recognized globally for its
significant contributions to the field of deep learning, Mila has
distinguished itself in the areas of language modelling, machine
translation, object recognition and generative models.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is
a global technology platform company with end-to-end solutions
empowering companies to discover and develop therapies against any
disease. The Company's experience and cutting-edge technologies
enable unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. ImmunoPrecise's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information, visit
www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release
contains statements that, to the extent they are not recitations of
historical fact, may constitute "forward-looking statements" within
the meaning of applicable Canadian securities laws. The Company
uses words such as "may", "would", "could", "will", "likely",
"expect", "believe", "intend", "should" and similar expressions to
identify forward-looking statements. Any such forward-looking
statements are based on assumptions and analyses made by
ImmunoPrecise in light of its experience and its perception of
historical trends, current conditions and expected future
developments. However, whether actual results and developments will
conform to ImmunoPrecise's expectations and predictions is subject
to any number of risks, assumptions and uncertainties. Many factors
could cause ImmunoPrecise's actual results to differ materially
from those expressed or implied by the forward-looking statements
contained in this news release. Such factors include, among other
things, actual revenues and earnings for IPA being lower than
anticipated, and those risks and uncertainties described in
ImmunoPrecise's annual management discussion and analysis for the
previous quarter ended July 31, 2020
which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-antibodies-and-mila-announce-strategic-ai-partnership-301165557.html
SOURCE ImmunoPrecise Antibodies Ltd.